secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0001104659-22-108996
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharma announces positive Phase 3 RAPID trial results for etripamil in PSVT
--------------------------------------------------------------------------------

- Primary endpoint met: 64.3% of etripamil patients converted to sinus rhythm within 30 min vs 31.2% placebo (HR=2.62, p<0.001).
- Safety profile consistent with prior trials; no serious AEs related to etripamil; majority of AEs mild (68%) to moderate (31%).
- Pooled data show statistically significant reduction in medical interventions and ED visits.
- Company plans to submit NDA to FDA in mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922108996/0001104659-22-108996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922108996/tm2228338d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-108996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer